NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ...

Underscores Royalty Pharma’s commitment to enhanced corporate governance following acquisition of its external manager ...

Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...